Clene Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs
22.02.2024 - Two “Compassionate Use” Expanded Access Programs (EAPs) provided access to treatment with CNM-Au8 to more than 250 people living with amyotrophic lateral sclerosis (ALS).A significant survival benefit (p=0.0001) was observed in EAP participants ... Seite 1
Natural History Consortium Clene Nanomedicine Inc Clene Inc Access Programs Clene Nanomedicine Clene Chart
Source: wallstreet-online.de